All News
Opioid Use in Rheumatoid Arthritis
Opioid use and abuse is at an all time high. Epidemiologic and public health analyses have led to greater stringency and attempts to limit use have adversely effected those with arthritis.
Read Article
Baricitinib Benefits Refractory RA
The small molecule oral JAK inhibitor baricitinib was effective for patients with highly refractory rheumatoid arthritis, a phase III study found.
Read Article
1 in 2 Americans Have Musculoskeletal Conditions
A recent report from the United States Bone and Joint Initiative (USBJI) estimates that 126.6 million Americans (one in two adults) are affected by a musculoskeletal (MSK) condition; a number on par with the number of Americans living with a chronic lung or heart conditions.
Read Article
High Mortal Risk in Rheumatoid Arthritis Following Arthroplasty
Rheumatoid arthritis (RA) is associated with an increased risk of myocardial infarction (MI) and post-MI fatality compared with the general population. At issue is whether this applies to those undergoing a surgical procedure.
Read Article
DMARDs Combo Cuts Time to First Remission in RA
A three-therapy protocol did not prove superior for achieving remission in rheumatoid arthritis (RA) patients after 1 year, but the regimen did lead to a shorter time until first remission versus a step-up approach, according to an analysis of the DREAM registry.
Read Article
Hemochromatosis Reviewed
Powell et al have published in Lancet a review of hemochromatosis; its genetics, pathogenesis, clinical manifestations and management.
Read Article
The Week in Review 18 March 2016
See the highlights from the past week that appeared on RheumNow.com, and watch Dr. Jack Cush as he reviews each of them.
Read Article
January/February 2016 Top Social Media News
In February 2016, RheumNow published 82 tweets about impactful news, research and teaching points that impact the rheumatology community. These feeds had a reach (impressions) of 80,800 with, 76 mentions, and over 2700 visits to learn on RheumNow.com.
Read Article
Sclerostin Inhibition May Worsen Rheumatoid Arthritis
Sclerostin, an inhibitor of the Wnt/β-catenin pathway, negatively regulates osteoblast differentiation and has anti-anabolic effects on bone formation. Thus, inhibition of sclerostin is currently being studied as therapy for postmenopausal osteoporosis.
Read Article
TNF Inhibitors Increase Perioperative Infection Risk
The use of tumour necrosis factor α inhibitors (TNFis) at the time of major surgery has been a challenge for surgeons, rheumatologists and those wishing to develop evidence-based guidelines for this clinical scenario.
Read Article
IL-6 Inhibition Makes News
Several new interleukin-6 inhibitors made headlines this week. While none of the new IL-6 inhibitors are soon to be approved and available, these studies may redefine the role of other non-TNF biologics in the future.
Read Article
New CDC Guidelines on Prescribing Opiates for Pain
The use of opioids has become increasingly problematic in the last few years. First, the rising rates of use and abuse, followed by greater restrictions and regulations that have curtailed use, and, finally, a resultant increase in illicit drug use (heroin) and opioid overdoses.
Read Article
Leflunomide and Weight Loss in Rheumatoid Arthritis
Weight change can have substantial effects on the outcomes of patients with arthritis. It has long been known that weight loss and low body mass index (BMI) are associated with poorer arthritis outcomes.
Read Article
ACR Invites Comment on Perioperative Management Guidelines
The ACR is inviting members and rheumatologists to comment on their proposal to develop recommendations for the "Perioperative Management of Rheumatic Disease Medications in Total Joint Arthroplasty of the Hip and Knee".
Read Article
Combined Dermatology-Rheumatology Clinics Benefits Patients
Healio reports that patients followed in a combined Dermatology and Rheumatology clinic in Canada revealed high patient satisfaction.
Read Article
Biosimilars Reviewed by Expert Panel
As the number of biosimilars in development keeps on growing, reaching nearly 700 products to date, demand for data from randomized controlled trials (RCTs) and an understanding of these new biologics is peaking the interest of many.
Read Article
Novel Protein as a Potential Autoantigen in JIA
Juvenile idiopathic arthritis (JIA) is clearly not related to rheumatoid arthritis and until recently has no identifiabile autoantigen linked to JIA.
Read Article
